<DOC>
	<DOCNO>NCT02857530</DOCNO>
	<brief_summary>Efficacy Safety Recombinant human thrombopoietin patient severe aplastic anemia severe aplastic anemia , randomize , double-blind , placebo-controlled , II phase , multi-center clinical research .</brief_summary>
	<brief_title>Efficacy Safety Thrombopoietin In Patients With Severe Very Severe Aplastic Anemia</brief_title>
	<detailed_description>rhTPO</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Able provide write informed consent Have severe severe aplastic anemia Have diagnosis Fanconi anemia Have infection adequately respond appropriate therapy Have Paroxysmal Nocturnal Hemoglobinuria ( PNH ) clone size neutrophil great equal 50 % Have creatinine and/or blood urea nitrogen ( BUN ) ≥2 time upper limit normal Have serum bilirubin ≥ 1.5 time upper limit normal , ≥4.0 time upper limit normal patient treat AntiThymocytes globulin（ATG） within three week screen . Have glutamicoxaloacetic transaminase （AST） and/or glutamicpyruvic transaminase （ALT） ≥ 3 time upper limit normal Are female nursing pregnant unwilling take oral contraceptive refrain pregnancy childbearing potential Have Eastern Cooperative Oncology Group ( ECOG ) performance status 3 great Have Thrombopoietin ( TPOR ) agonists medication previous 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>